A detailed history of John G Ullman & Associates Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, John G Ullman & Associates Inc holds 1,055 shares of ABBV stock, worth $246,870. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,055
Holding current value
$246,870
% of portfolio
0.04%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 05, 2025

BUY
$184.85 - $231.54 $195,016 - $244,274
1,055 New
1,055 $244,000
Q1 2024

May 06, 2024

BUY
$159.82 - $182.1 $194,980 - $222,162
1,220 New
1,220 $222,000
Q1 2023

May 05, 2023

BUY
$144.61 - $166.54 $213,878 - $246,312
1,479 New
1,479 $236,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $414B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track John G Ullman & Associates Inc Portfolio

Follow John G Ullman & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of John G Ullman & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on John G Ullman & Associates Inc with notifications on news.